Market News AIOpen the app

Minerva Neurosciences made $100.7 million last quarter and shared news about its schizophrenia study.

ResultsRead the original at globenewswire.com
Neutral

Minerva's reported profit came mainly from a non-cash warrant gain, and it also had an adjusted loss as research costs rose. Its Phase 3 study continues, but no new trial result changes the company's prospects.

NERV · Minerva Neurosciences

AI read · Neutral

The AI's read

The reported profit came from a paper accounting gain, not from the company's operations. Its adjusted loss and higher research spending show the company is still spending more than it brings in. The Phase 3 study continues, but the report gives no new trial result to change the view of the drug.

Get alerts for NERV

Follow Minerva Neurosciences (NERV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NERV
Free on the App Store and Google Play, or on the web.